紫杉醇联合铂类化疗对晚期卵巢上皮细胞癌患者CD4^+CD25^+FOXP3^+细胞的影响及意义被引量：10

The influence and significance for CD4^+CD25^+FOXP3^+ Cells by paclitaxel plus platinum chemotherapy in patients with advanced epithelial ovarian carcinoma

下载PDF

导出

摘要目的观察紫杉醇联合铂类方案化疗对晚期卵巢上皮细胞癌患者的外周血中CD4+CD25+FOXP3+阳性细胞率的变化,并观察此变化与患者化疗疗效及与CA125等肿瘤标志物的相关性,是否可作为晚期卵巢上皮性癌化疗疗效的预测指标。方法选择36例卵巢上皮性癌患者,均有病理证实,为术后复发或姑息性减瘤术后,应用FACS检测患者化疗前、2周期、4周期、6周期化疗后外周血CD4+CD25+FOXP3+细胞阳性率,同时检测CD4+/CD8+比值。观察终点为出现病情进展,记录无疾病进展时间。结果 CD4+CD25+FOXP3+细胞阳性率在化疗敏感性(CR+PR)患者中下降明显,尤其是PR患者。而在化疗后进展的患者中无明显变化,甚至有上升趋势。CD4+/CD8+比值在化疗敏感性(CR+PR)患者中升高,而在进展患者中无变化,甚至下降。结论晚期卵巢上皮癌患者中外周血中CD4+CD25+FOXP3+细胞阳性率在化疗前后的变化与患者化疗疗效相关,可作为预测化疗疗效的一项预测指标。 Objective To observe the changes of CD4＋CD25＋ FOXP3＋ positive cell rate in patients with advanced epithelial ovarian carcinoma treated by chemotherapy with paclitaxel plus platinum and we also observe the relationship between the changes and the efficacy of chemotherapy.And to observe whether it can be used as a effect forecast index for advanced epithelial ovarian cancer before chemotherapy.Methods A total of 36 cases in the group.All the cases were histologically confirmed as epithelial ovarian cancer,postoperative relapse or palliative debulking surgery.FACS detects the positive rate of peripheral blood CD4＋CD25＋FOXP3＋ cells.Simultaneouly,we detect the ratio of CD4＋/CD8＋ cells by FACS.The endpoint of observation was the progress of disease and we record the time to progression.Results The positive rate of CD4＋CD25＋FOXP3＋cells decreased significantly in the patients with CR＋PR,especially in patients with PR.While in the progressed after chemotherapy,there is no obvious changes,and it even has a tendency to rise.CD4＋/CD8＋ ratio in the sensitivity to chemotherapy（CR＋PR） elevated,and in the progression,it has no change,or even declines.Conclusion The changes of CD4＋CD25＋FOXP3＋cells positive rate in the patients with advanced epithelial ovarian cancer before and after chemotherapy related to the efficacy of chemotherapy,which can be used as a predictor of chemotherapeutic efficacy.

作者于荣侯建青

机构地区青岛大学医学院附属烟台毓璜顶医院妇产科

出处《滨州医学院学报》 2012年第4期248-251,共4页 Journal of Binzhou Medical University

关键词卵巢癌 FOXP3基因化疗 Ovarian cancer FOXP3 gene Chemotherapy

分类号 R711.75 [医药卫生—妇产科学]

引文网络
相关文献

参考文献8

1万德森.临床肿瘤学[M].北京:人民卫生出版社,2011:465.
2张育超,王惠英,罗招凡.胃癌患者外周血CD4^+CD25^+调节性T细胞的变化[J].实用医学杂志,2007,23(17):2675-2676. 被引量：5
3Liu li, yao jun xia, ding qian,et al. CIM+CD25+high regulatory cellin peripheral blood of nsclc[ J. acta of huazhong uni of sci and technology [ medsci ] ,2006,26 (5) :548-550.
4Rosenberg sa. progress in human tumour immunology and immuno- therapy[ J]. nature ,2001,411 (6835) :380-4.
5Ormandy' LA, Hillemann T, Wedemeyer H, et al. Increased popula- tions of regulatory T ceils in peripheral blood of patients with hepato- cellular carcinoma J. Cancer Res,2005,65(6) :2457-2464.
6Pamess J, Horwitzs SB. Taxol bines to polymerized microtubules in vitro[ J]. Cell Biol, 1981,91:479-487.
7Blume E. Agreement to develope taxotere expected in April [ J ]. Nat Cancer Inst, 1992,84:673-678.
8Goldberg JM, Piver MS, Hempling RE, et al. Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer[ J]. Gyncol Oncol, 1996, 63 : 312-317.

二级参考文献4

1Sakaguchi S,Sskaguchi N,Asano M,et al.Immunologic selftolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25).Breakdown of a single mechanism of selftolerance causes various autoimmune diseases[J].J Immunol,1995,155(3):1151-1164.
2Belkaid Y,Piccirillo C A,Mendez S,et al.CD4^+CD25^+ regulatory T cells control Leishmania major persistence and immunity[J].Nature,2002,420 (6915):502-507.
3Barrat F J,Cua D J,Boonstra A,et al.In vitro generation of interleukin-10-producing regulatory CD4^+ T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (TH1)and TH2-inducing cytokines[J].J Exp Med,2002,195(5):603-616.
4Jordan M S,Boesteanu A,Reed A J,et al.Thymic selection of CD4^+CD25^+ regulatory T cells induced by an agonist self-peptide[J].Nature Immunol,2001,2(4):301-306.